Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity

Diabetes

Volumn 50, Issue 5, 2001, Pages 1110-1118

  Yakar, Shoshana ^a   Liu, Jun Li ^a   Fernandez, Ana M ^a   Wu, Yiping ^a   Schally, Andrew V ^b   Frystyk, Jan ^c   Chernausek, Steve D ^d   Mejia, Wilson ^a   Le Roith, Derek ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR ANTAGONIST; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE ANTAGONIST; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DIET RESTRICTION; GENE DELETION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GROWTH HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIVER; MALE; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; WHITE ADIPOSE TISSUE;

EID: 0035033682     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.5.1110     Document Type: Article

References (49)

1. Genetic engineering in mice: Impact on insulin signalling and action
2. Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: Effects of starvation, refeeding, and dieting
3. Insulin-dependent regulation of insulin receptor concentrations: A direct demonstration in cell culture
4. Insulin binding to liver plasma membranes in the obese hyperglycemic (ob/ob) mouse: Demonstration of a decreased number of functionally normal receptors
5. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene
6. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance
7. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect sinular to that in type 2 diabetes
8. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1
9. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2
10. Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes
11. IGF-I is required for normal embryonic growth in mice
12. Role of insulin-like growth factors in embryonic and postnatal growth
13. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)
14. Insulin-like growth factor I: Physiology, metabolic effects and clinical uses
15. Normal growth and development in the absence of hepatic insulin-like growth factor I
16. Growth hormone insulin-like growth factor I axis in insulin-dependent diabetes mellitus
17. IGF-I and diabetes in adolescence
18. Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: Manipulation using the Cre/loxP system in transgenic mice
19. Suppression of insulin-like growth factor I during epidermal growth factor-induced growth retardation
20. Changes in the circulating IGF system during short-term fasting and refeeding in rats
21. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone
22. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: Mechanisms of action
23. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly
24. Inhibition of GH release of rats by new potent antagonists of growth hormone-releasing hormone (GHRH)
25. Transgenic models of growth hormone action
26. Physiology of growth hormone secretion and action
27. Insulin resistance in acromegaly: Defects in both hepatic and extrahepatic insulin action
28. Insulin resistance: Mechanisms, syndromes, and implications
29. Metabolic effects of hypopituitarism and acromegaly
30. Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice
31. Growth hormone-induced insulin resistance: Role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4
32. Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues
33. Identification of enhanced serine kinase activity in insulin resistance
34. Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway
35. The crucial role of a phosphatase in insulin resistance and obesity
36. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1
37. Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signaling
38. JAK1-dependent phosphorylation of insulin receptor substrate-1 (IRS-1) is inhibited by IRS-1 serine phosphorylation
39. Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats
40. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1
41. Growth factor control of pancreatic B cell hyperplasia
42. Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion
43. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects
44. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion
45. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans
46. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: Evidence for in vivo biological activity
47. Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes
48. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes
49. Insulin-like growth factor [ inhibits glucose-stimulated insulin secretion but does not impair glucose metabolism in normal humans